Evaluation of Cardiovascular Risk Profile and Risk Scores of Antiretroviral Therapy-naive HIV Patients in Eastern India

被引:0
|
作者
Chaubey, Manaswi [1 ]
Chakravarty, Jaya [1 ]
Gupta, Rishabh [1 ]
Jethwani, Parth [1 ]
Puri, Rahul [1 ]
Sundar, Shyam [1 ]
机构
[1] Banaras Hindu Univ, Inst Med Sci, Dept Gen Med, Varanasi, Uttar Pradesh, India
关键词
Antiretroviral therapy; cardiovascular disease; cardiovascular disease risk; cardiovascular risk score; human immunodeficiency virus; people living with human immunodeficiency virus; ACUTE MYOCARDIAL-INFARCTION; HEART-DISEASE RISK; INFECTION; INDIVIDUALS; ASSOCIATION; POPULATION;
D O I
10.4103/jgid.jgid_29_24
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: People living with human immunodeficiency virus (PLHIV) are known to have an increased prevalence of traditional cardiovascular risk factors and are at a higher risk of cardiovascular disease (CVD). This study was done to assess the CVD risk factors in treatment naive PLHIV in a center of the national program. Methods: In this cross-sectional explorative study, traditional CVD risk factors were assessed, and 10-year Framingham and atherosclerotic cardiovascular disease (ASCVD) risk score were calculated in treatment naive PLHIV attending the antiretroviral therapy (ART) center, IMS, BHU. Results: The study included 337 ART naive patients. The prevalence of CVD risk factors in treatment naive PLHIV - were low high-density lipoprotein cholesterol levels (81.4%), high triglyceride levels (32.7%), smoking (32.3%), obesity (13.6%), hypertension (5%), diabetes (2.7%), and high low-density lipoprotein cholesterol levels (2.1%). Moderate-to-high 10-year Framingham Risk Score and American Heart Association/American College of Cardiology 10-year ASCVD risk score were 10.8% and 8.9%, respectively. In Framingham Risk Score, age >= 40 years (odds ratio [OR] - 131) (95% confidence interval [CI] - 6.5-1043) alcohol intake (OR - 5.14 [95% CI - 1.82-14.46] and presence of tuberculosis (OR - 4.78) (95% CI - 1.48-15.40), while in ASCVD risk score history of alcohol intake (OR - 26.20 [95% CI - 3.1-216.8] were at higher risk of CVD in multivariate variate analysis. Conclusion: CVD risk factors were common among ART naive patient. Thus, screening, education, and treatment of CVD risk factors should be done in these patients at initiation of care.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 50 条
  • [31] The Influence of Social Networks on Antiretroviral Therapy Initiation Among HIV-Infected Antiretroviral Therapy-Naive Youth in Rural Kenya and Uganda
    Brown, Lillian B.
    Balzer, Laura B.
    Kabami, Jane
    Kwarisiima, Dalsone
    Sang, Norton
    Ayieko, James
    Chen, Yiqun
    Chamie, Gabriel
    Charlebois, Edwin D.
    Camlin, Carol S.
    Cohen, Craig R.
    Bukusi, Elizabeth
    Kamya, Moses R.
    Moody, James
    Havlir, Diane V.
    Petersen, Maya L.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 83 (01) : 9 - 15
  • [32] Cardiometabolic risk factors among HIV patients on antiretroviral therapy
    Kiage, James N.
    Heimburger, Douglas C.
    Nyirenda, Christopher K.
    Wellons, Melissa F.
    Bagchi, Shashwatee
    Chi, Benjamin H.
    Koethe, John R.
    Arnett, Donna K.
    Kabagambe, Edmond K.
    LIPIDS IN HEALTH AND DISEASE, 2013, 12
  • [33] Comparative Evaluation of Prevalence, Risk Factors, and Pathologic Features of Kidney Disease in Highly Active Antiretroviral Therapy-Naive and Highly Active Antiretroviral Therapy-Experienced Patients at a Tertiary Health Facility in Maiduguri, Northeastern Nigeria
    Sulaiman, Mohammad Maina
    Shettima, Jummai
    Ummate, Ibrahim
    Arogundade, Fatiu Abiola
    Yusuph, Haruna
    Nwankwo, Emeka
    Sanusi, Abubakr Abefe
    Akinsola, Adewale
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2022, 33 (01) : 72 - 79
  • [34] The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients
    Masia, Mar
    Bernal, Enrique
    Padilla, Sergio
    Luisa Graells, Maria
    Jarrin, Inmaculada
    Vicenta Almenar, Maria
    Molina, Juan
    Hernandez, Ildefonso
    Gutierrez, Felix
    ATHEROSCLEROSIS, 2007, 195 (01) : 167 - 171
  • [35] Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study
    Dorjee, Kunchok
    Baxi, Sanjiv M.
    Reingold, Arthur L.
    Hubbard, Alan
    BMC INFECTIOUS DISEASES, 2017, 17
  • [36] Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of Inflammatory Markers More Than Antiretroviral Drugs Alone in Antiretroviral Therapy-Naive HIV-Infected Patients
    Calza, Leonardo
    Vanino, Elisa
    Salvadori, Caterina
    Manfredi, Roberto
    Colangeli, Vincenzo
    Cascavilla, Alessandra
    Di Bari, Maria Assunta
    Motta, Roberto
    Viale, Pierluigi
    HIV CLINICAL TRIALS, 2014, 15 (01): : 1 - 13
  • [37] Peripheral arterial disease in antiretroviral therapy naive HIV infected patients - A single centre case control study from Eastern India
    Khanra, Dibbendhu
    Mukherjee, Anindya
    Talukdar, Arunansu
    Sinha, S. K.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2019, 5 (03) : 197 - 207
  • [38] HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults
    Lipshultz, Steven E.
    Mas, Catherine M.
    Henkel, Jacqueline M.
    Franco, Vivian I.
    Fisher, Stacy D.
    Miller, Tracie L.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (06) : 661 - 674
  • [39] Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review
    Souza, Suelen Jorge
    Luzia, Liania Alves
    Santos, Sigrid Sousa
    Carvalho Rondo, Patricia Helen
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2013, 59 (02): : 186 - 198
  • [40] Cardiovascular risk associated with antiretroviral therapy in IV-infected patients
    Calza, Leonardo
    Manfredi, Roberto
    Chiodo, Francesco
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (11) : 1497 - 1516